Persantine
(dipyridamole)ApprovedSmall molecule
Boehringer IngelheimDipyridamole is used to prevent blood clots and reduce the risk of stroke, particularly in patients with heart valve replacements or certain heart conditions. It works by helping to keep blood flowing smoothly and preventing platelets from sticking together.[2] Persantine is currently approved and in use across 19 indications[4].[1]
Persantine is one of 502 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
19
Indications
29
Total Trials
2
Active Trials
501
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Persantine
Boehringer IngelheimApproved
Spikevax
ModernaPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Nexavar
BayerPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Glucocorticoid
AbbViePreclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Portal vein thrombosis3 trials
Rheumatoid Arthritis2 trials
Treatment2 trials
COVID-192 trials
17 more indications
Ischemia2 trials
Pancreatic Cancer1 trial
Aspirin1 trial
Immune Response1 trial
Kidney Transplant1 trial
Ovarian Cancer1 trial
Efficacy1 trial
Efficacy of Allopurinol and Dypiridamole in Acute Mania
Completed·—·Phase 4·NCT00560079·180 enrolled
Coronary Artery Bypass1 trial
Pterygium1 trial
Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium
Unknown status·—·Phase 2·NCT02782260·40 enrolled
Atrial Fibrillation1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 22, 1986
PERSANTINE
NDA NDA012836
Dec 13, 1990
IV PERSANTINE
NDA NDA019817
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Persantine drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for dipyridamole. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 3',5'-Cyclic Phosphodiesterase Inhibitor; Equilibrative Nucleoside Transporter 1 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company